Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: the THETIS study
ISBT Education. Lai Y. Nov 27, 2017; 203507 Topic: Clinical trials
Yong Rong Lai
Yong Rong Lai
This content is exclusively available for members.

You may become an ISBT member here.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation the participant will be able to:

- Review incidence of thalassemia carriers in China and worldwide
- Relate studies and trials evaluating iron overload and chelation in Chinese thalassemia major and Non Transfusion Dependent Thalassemia (NTDT) patients
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies